Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,412,864 | 1,506,310 | 881,482 | 591,448 | 1,057,769 |
| Marketable Securities | 580,000 | 120,000 | N/A | N/A | 1,075,000 |
| Receivables | 716,765 | 705,794 | 651,493 | 563,360 | 396,490 |
| Inventories | 480,445 | 597,039 | 714,061 | 1,072,721 | 95,396 |
| Other current assets | 261,543 | 320,809 | 267,192 | 252,392 | 152,491 |
| TOTAL | $4,629,028 | $3,435,428 | $2,606,140 | $2,611,334 | $2,839,568 |
| Non-Current Assets | |||||
| PPE Net | 173,413 | 169,646 | 228,050 | 256,837 | 127,935 |
| Intangibles | 6,472,018 | 7,171,169 | 7,487,099 | 8,979,937 | 3,153,354 |
| Other Non-Current Assets | 737,798 | 617,116 | 513,966 | 450,532 | 415,044 |
| TOTAL | $7,383,229 | $7,957,931 | $8,229,115 | $9,687,306 | $3,696,333 |
| Total Assets | $12,012,260 | $11,393,360 | $10,835,250 | $12,298,640 | $6,535,901 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 31,000 | 604,954 | 31,000 | 31,000 | 246,322 |
| Accounts payable and accrued liabilities | 77,869 | 102,750 | 90,758 | 100,298 | 26,945 |
| Accrued Expenses | 910,947 | 793,914 | 803,255 | 666,304 | 352,732 |
| TOTAL | $1,038,573 | $1,536,692 | $933,193 | $809,303 | $653,745 |
| Non-Current Liabilities | |||||
| Long Term Debt | 6,077,640 | 5,107,988 | 5,693,341 | 6,018,943 | 1,848,516 |
| Deferred Revenues | N/A | N/A | 463 | 2,093 | 2,546 |
| Other Non-Current Liabilities | 125,552 | 163,976 | 178,650 | 204,198 | 241,183 |
| TOTAL | $6,879,928 | $6,119,670 | $6,816,328 | $7,524,145 | $2,222,411 |
| Total Liabilities | $7,918,501 | $7,656,362 | $7,749,521 | $8,333,448 | $2,876,156 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 60,732 | 62,345 | 63,331 | 61,739 | 56,325 |
| Common Shares | 61 | 61 | 61 | 61 | 61 |
| Retained earnings | 1,127,820 | 879,129 | 734,058 | 830,698 | 1,160,366 |
| Other shareholders' equity | -947,667 | -842,147 | -1,125,509 | -400,360 | -134,352 |
| TOTAL | $4,093,756 | $3,736,997 | $3,085,734 | $3,965,191 | $3,659,745 |
| Total Liabilities And Equity | $12,012,257 | $11,393,359 | $10,835,255 | $12,298,639 | $6,535,901 |